Synaptogenix
Synaptogenix is a clinical-stage biopharmaceutical company dedicated to developing targeted therapeutics for neurodegenerative diseases and developmental disorders. The company's primary focus is on bryostatin-1, a drug candidate that shows promise in treating Alzheimer's disease and is currently in clinical testing. Bryostatin-1's potential stems from its ability to activate protein kinase C (PKCϵ), which stimulates synaptic growth factors and enhances the activity of enzymes that degrade amyloid-β, while also preventing the transformation of Tau into neurofibrillary tangles. In addition to Alzheimer's, Synaptogenix is exploring bryostatin's applications for other conditions, including Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which are in various stages of pre-clinical development. Founded in 2012 and headquartered in New York, Synaptogenix operates independently to advance its innovative therapeutic platform.
CannaSoul Analytics is a pioneer in the analysis of cannabis-based products, treatments, and pharmaceuticals, founded by Shmuel Mandel in 2018. The company specializes in the comprehensive analysis of over 100 cannabinoids and 100 terpenes, as well as offering unique endocannabinoid analysis across various matrices. CannaSoul is dedicated to advancing drug discovery through the development of botanical medicine and therapeutics derived from natural compounds. Its services include cannabis molecular analysis, intellectual property licensing, and clinical and pre-clinical trials. Additionally, CannaSoul engages in the screening of cannabis and psilocybin extracts, isolated cannabinoids, and novel molecules using various cell line models, thereby facilitating the integration of botanical medicine into the pharmaceutical industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.